Using CPX-351 to treat patients with high-risk blood cancers
Official title: Phase 1 Dose Escalation Study of CPX-351 for Patients With Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia After Failure to Hypomethylating Agents
Run by M.D. Anderson Cancer Center · NCT03896269 · Data updated 2026-11-12
This study is testing a new treatment called CPX-351 to see if it can safely help people with high-risk blood cancers like myelodysplastic syndrome or chronic myelomonocytic leukemia.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 38 (estimated) |
| Sponsor | M.D. Anderson Cancer Center Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy, radiation |
| Locations | 1 site (Houston, Texas) |
| Status | Recruiting |
| Started | May 14, 2019 |
| Main results expected | December 31, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | October 6, 2026 |
| Trial ID | NCT03896269 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients diagnosed with intermediate-2 or high-risk MDS or CMML who have not responded to previous therapies and are not eligible for stem cell transplant.
✕Probably not a fit
Patients with low-risk MDS or CMML or those who have not exhausted other treatment options may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This phase I trial investigates the safety, tolerability, and efficacy of liposome-encapsulated daunorubicin-cytarabine (CPX-351) in patients with relapsed or refractory high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML). The study involves a dose-escalation approach to determine the maximum tolerated dose and assess the overall response rate, survival, and safety profile of the treatment. Patients will receive the drug intravenously over specified days, with follow-up assessments to evaluate treatment outcomes.
Why it matters
Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with high-risk MDS or CMML who have limited treatment alternatives.
How similar studies have gone: Other studies have shown promise with similar chemotherapy approaches, but this specific combination is being evaluated for the first time in this patient population.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of MDS or chronic myelomonocytic leukemia (CMML) according to World Health Organization (WHO) * Patients are either not eligible for or choose not to proceed with a stem cell transplant at the time of enrollment * MDS and CMML classified by International Prognostic Scoring System (IPSS) as intermediate-2/high risk with excess blasts \> 5%, or with 10-19% bone marrow blasts * No response following at least 4 cycles of therapy or relapse after initial CR, partial response (PR), or HI or progression after any number of cycles of either azacitidine, decitabine, guadecitabine or ASTX727 (oral decitabine) as single agents or in combination with other investigational agents * Patient (or patient's legally authorized representative) must have signed an informed consent document indicating that the patient understands the purpose of and procedures required for the study and is willing to participate in the study * Total bilirubin \< 3 mg/dL (will allow less than 5 x upper limit of normal \[ULN\] if Gilbert's at investigator's discretion) * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =\< 3 x ULN * Serum creatinine clearance \> 30 mL/min and no end/stage renal disease * Hydroxyurea for control of leukocytosis or use of hematopoietic growth factors (eg, granulocyte-colony stimulating factor \[G-CSF\], granulocyte-macrophage colony-stimulating factor \[GM-CSF\], procrit, aranesp, thrombopoietins) is allowed at any time prior to or during study if considered to be in the best interest of the patient Exclusion Criteria: * New York Heart Association (NYHA) class III or IV congestive heart failure or left ventricular ejection fraction (LVEF) \< 50 by echocardiogram or multigated acquisition (MUGA) scan * History of myocardial infarction within the last 6 months or unstable/uncontrolled angina pectoris or history of severe and/or uncontrolled ventricular arrhythmias * Uncontrolled infection not adequately responding to appropriate antibiotics * Female patients who are pregnant or lactating * Patients with reproductive potential who are unwilling to following contraception requirements (including condom use for males with sexual partners, and for females: prescription oral contraceptives \[birth control pills\], contraceptive injections, intrauterine devices \[IUD\], double-barrier method \[spermicidal jelly or foam with condoms or diaphragm\], contraceptive patch, or surgical sterilization) throughout the study * Female patients with reproductive potential who have a positive urine or blood beta-human chorionic gonadotropin (beta HCG) pregnancy test at screening * Patients receiving any other concurrent investigational agent or chemotherapy, radiotherapy, or immunotherapy (within 14 days of initiating study treatment) * Prior cumulative anthracycline exposure of \> 550 mg/m\^2 daunorubicin or equivalent, or \> 400 mg/m\^2 in patients who received radiation therapy to the mediastinum
Where it's running
-
M D Anderson Cancer Center
Houston, Texas, United States Recruiting
Study contacts
- Principal investigator: Guillermo M Bravo — M.D. Anderson Cancer Center
- Study coordinator: Guillermo M Bravo
- Email: gmontalban1@mdanderson.org
- Phone: 713-794-3604
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Decitabine plus FLAG‑Ida chemotherapy and total‑body irradiation before donor stem cell transplant for adults with high‑risk myeloid cancers
This test tries whether adding decitabine to FLAG‑Ida chemotherapy and total‑body irradiation before a donor stem cell transplant helps adults with high‑risk or relapsed myeloid blood cancers live longer and stay in remission.
-
Q702 to treat blood cancers
This Phase 1 trial will test whether the oral drug Q702 is safe, tolerable, and what dose works best for adults with certain blood cancers who have failed or are not eligible for standard treatments.
-
Onvansertib treatment for recurrent or refractory chronic myelomonocytic leukemia and related conditions
This study is testing a new drug called onvansertib to see if it can help people with recurring chronic myelomonocytic leukemia and related blood disorders feel better and respond to treatment.
-
Chemotherapy and Stem Cell Transplant for Relapsed or Refractory Blood Cancers
This study is testing a combination of two chemotherapy treatments and total body radiation to see if it helps people with relapsed or hard-to-treat blood cancers get ready for a stem cell transplant.
-
Treatment of low or intermediate-risk myelodysplastic syndromes and chronic myelomonocytic leukemia with canakinumab
This study is testing if a new medication called canakinumab can help people with low or intermediate-risk myelodysplastic syndromes and chronic myelomonocytic leukemia feel better and reduce their need for blood transfusions.
-
Combining azacitidine, venetoclax, and gilteritinib for treating FLT3-mutated blood cancers
This study is testing a new combination of three medications to see if they can help people with certain types of blood cancers that have a specific genetic mutation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.